Cargando…
Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors: A single-center analysis
The advent of imatinib mesylate (IM) has dramatically revolutionized the prognosis of advanced and metastatic/recurrent gastrointestinal stromal tumors (GISTs). The objective of this retrospective study is to investigate the safety and efficacy of combination of surgery following IM treatment in the...
Autores principales: | Wang, Jian, Yin, Yuan, Shen, Chaoyong, Yin, Xiaonan, Cai, Zhaolun, Pu, Lin, Fu, Wei, Wang, Yaxuan, Zhang, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478449/ https://www.ncbi.nlm.nih.gov/pubmed/32118738 http://dx.doi.org/10.1097/MD.0000000000019275 |
Ejemplares similares
-
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
por: Shen, Chaoyong, et al.
Publicado: (2014) -
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017) -
Pediatric pancreatic teratoma: A case report and literature review
por: Wang, Jian, et al.
Publicado: (2019) -
Surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors: a protocol for a systematic review and meta-analysis update
por: Cai, Zhaolun, et al.
Publicado: (2021) -
Clinicopathological features, clinical efficacy on 101 cases of rectal gastrointestinal stromal tumors, and the significance of neoadjuvant therapy
por: Yang, Hongxin, et al.
Publicado: (2021)